Novavax, Inc. has released the results of the initial cohort of its COVID-19-influenza combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (TNIV) phase 3 trial.

Shares of Novavax (NVAX) rose 0.58% to close at $8.67 on Tuesday, ending a six-session slide. The stock has fallen around 18% between June 1 and June 8, compared to a 2.56% decline in the S&P 500 over ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Hello, everyone. Welcome to the Jefferies Healthcare Conference here in New York. It's a pleasure. Thank you for tuning in, everyone in New York and online. I'm here joined by Novavax, Jim, John, ...